Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shield Therapeutics ( (GB:STX) ) just unveiled an announcement.
Shield Therapeutics reported its strongest year to date in 2025, driven by a 56% increase in U.S. ACCRUFeR net revenue to about $46 million, making the drug the number one branded prescription oral iron in the U.S. market. Group net revenues and other income rose to $49.7 million, losses narrowed to $17.7 million and the company achieved positive operating cash flow in the fourth quarter, supported by higher pricing, increased prescriptions and tighter cost control.
The group also expanded its balance sheet flexibility by amending and upsizing its senior secured debt facility to up to $50 million, earmarking part of the capacity for potential M&A. Regulatory and geographic expansion continued, with FDA approval to extend ACCRUFeR’s indication to adolescents, launches or approvals in Canada and South Korea, and progress toward approvals in China and Japan, positioning Shield for broader global penetration in the iron deficiency market.
Shield is further strengthening investor engagement with a new interactive investor hub and has scheduled its annual general meeting for June in the U.K. The combination of market-share gains, improving cash generation and an enlarged financing facility suggests a transition toward sustainable profitability and provides additional strategic options for shareholders and partners.
The most recent analyst rating on (GB:STX) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on STX Stock
According to Spark, TipRanks’ AI Analyst, STX is a Neutral.
The overall stock score is primarily influenced by the company’s robust technical momentum and positive corporate events, which are offset by significant financial challenges and valuation concerns. The strong technical indicators and strategic corporate developments provide optimism, but financial instability remains a critical risk.
To see Spark’s full report on STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics is a commercial-stage specialty pharmaceutical group focused on treating iron deficiency and iron deficiency anemia with its oral ferric maltol product, marketed as ACCRUFeR in the U.S. and FeRACCRU in other territories. The company targets a sizeable iron deficiency market through direct U.S. commercialization and licensing partnerships across Europe, Canada, China, Korea, Japan and other regions, with patent protection extending into the mid-2030s.
Average Trading Volume: 2,083,281
Technical Sentiment Signal: Buy
Current Market Cap: £92.95M
Learn more about STX stock on TipRanks’ Stock Analysis page.